Publications by authors named "S Katakura"

: This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial-mesenchymal transition (EMT) within the tumor microenvironment (TME). : We employed an in vitro three-dimensional organoid model that mirrors the physiology of human lung cancer. These organoids consist of lung cancer cells harboring specific mutations, human mesenchymal stem cells, and human umbilical vein endothelial cells.

View Article and Find Full Text PDF

The interactions between zooplankton and viruses, which have been overlooked despite their crucial roles in marine ecosystems, are investigated in the copepod Pseudocalanus newmani. Copepod transcriptome data reveal four novel RNA viruses and weekly zooplankton samplings detect all viruses with different prevalence peaks during low-abundance periods of P. newmani.

View Article and Find Full Text PDF
Article Synopsis
  • The text indicates that there is a correction to a previously published article.
  • The article is identified by its DOI (Digital Object Identifier): 10.1371/journal.pone.0277770.
  • This correction aims to address errors or issues found in the original publication.
View Article and Find Full Text PDF

Purpose: Genetic mutation detection has become an important step in nonsmall-cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mutations prior to treatment is thus necessary. Currently, either next-generation sequencing (NGS)-based or polymerase chain reaction (PCR)-based tests are used.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the safety and effectiveness of combining immune checkpoint inhibitors (ICI) with chemotherapy as a first-line treatment for older adults (75+) with advanced non-small cell lung cancer (NSCLC).
  • Conducted across 58 centers in Japan, the research analyzed 1,245 patients, focusing on their overall survival (OS) and progression-free survival (PFS) based on different treatment approaches.
  • Findings revealed that the median OS for those treated with ICI-chemotherapy was around 20 months, similar to patients receiving ICI alone, suggesting no significant difference in outcomes among treatment types after adjusting for various factors.
View Article and Find Full Text PDF